Quarterly report pursuant to Section 13 or 15(d)

Agreements with Incyte Corporation - Collaboration Agreement (Details)

v3.8.0.1
Agreements with Incyte Corporation - Collaboration Agreement (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 08, 2018
Mar. 31, 2018
Agreements with Incyte Corporation    
Revenue recognized   $ 400
Deferred revenue    
Deferred revenue, current   10,272
Deferred revenue, long-term   1,610
Incyte | Collaboration Agreement    
Agreements with Incyte Corporation    
Up-front consideration $ 10,000  
Up-front consideration, cash 2,500  
Up-front consideration, pre-paid research funding 7,500  
Maximum target selection milestone payments and option exercise fees the Company is eligible to receive 54,000  
Maximum development and regulatory milestone payments the Company is eligible to receive for each of the validated targets 50,000  
Maximum commercial milestone payments the Company is eligible to receive for each of the validated targets if products arising from collaboration are approved $ 65,000  
Period of written notice to terminate the agreement by Incyte 60 days  
Period of written notice to terminate the agreement by the Company in the event the counterparty or one of its affiliates or sublicensees challenges the validity or enforceability of certain patent rights controlled by the Company 30 days  
Period of written notice to terminate the agreement by either of the parties in the event of an uncured material breach of the collaboration agreement by the other party 30 days  
Total transaction price $ 12,300  
Upfront non-refundable and non-creditable payment 2,500  
Prepaid research amount 7,500  
Premium paid on equity investment $ 2,300  
Revenue recognized   400
Deferred revenue    
Deferred revenue, current   10,300
Deferred revenue, long-term   $ 1,600